[{"id":"4bdac475-2ce7-43c7-9fc6-1b82deed752b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05376800","created_at":"2022-05-17T12:54:19.363Z","updated_at":"2025-02-25T14:08:51.835Z","phase":"Phase 1","brief_title":"A Study to Determine How BI 907828 (Brigimadlin) is Taken up in the Tumor (Phase 0) and to Determine the Highest Dose of BI 907828 (Brigimadlin) That Could be Tolerated (Phase 1a) in Combination With Radiation Therapy in People With a Brain Tumor Called Glioblastoma","source_id_and_acronym":"NCT05376800","lead_sponsor":"Boehringer Ingelheim","biomarkers":" TP53","pipe":" | ","alterations":" TP53 wild-type • IDH wild-type","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 wild-type • IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e brigimadlin (BI 907828)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 11/07/2022","start_date":" 11/07/2022","primary_txt":" Primary completion: 08/29/2025","primary_completion_date":" 08/29/2025","study_txt":" Completion: 08/29/2025","study_completion_date":" 08/29/2025","last_update_posted":"2025-02-18"},{"id":"e403d404-bc05-4817-9ff3-f97c2077e32b","acronym":"","url":"https://clinicaltrials.gov/study/NCT03449381","created_at":"2021-01-18T17:00:34.045Z","updated_at":"2025-02-25T14:15:08.572Z","phase":"Phase 1","brief_title":"This Study Aims to Find the Best Dose of BI 907828 (Brigimadlin) in Patients With Different Types of Advanced Cancer (Solid Tumors)","source_id_and_acronym":"NCT03449381","lead_sponsor":"Boehringer Ingelheim","biomarkers":" TP53 • MDM2","pipe":" | ","alterations":" TP53 wild-type","tags":["TP53 • MDM2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e brigimadlin (BI 907828)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 267","initiation":"Initiation: 06/20/2018","start_date":" 06/20/2018","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2025-02-18"},{"id":"9518cf2f-a488-48b8-a437-c584bd916e0c","acronym":"Brightline-2","url":"https://clinicaltrials.gov/study/NCT05512377","created_at":"2022-08-23T14:55:35.585Z","updated_at":"2025-02-25T15:19:58.742Z","phase":"Phase 2","brief_title":"Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder","source_id_and_acronym":"NCT05512377 - Brightline-2","lead_sponsor":"Boehringer Ingelheim","biomarkers":" TP53 • MDM2","pipe":" | ","alterations":" TP53 wild-type","tags":["TP53 • MDM2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e brigimadlin (BI 907828)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 99","initiation":"Initiation: 12/13/2022","start_date":" 12/13/2022","primary_txt":" Primary completion: 06/10/2025","primary_completion_date":" 06/10/2025","study_txt":" Completion: 06/10/2025","study_completion_date":" 06/10/2025","last_update_posted":"2025-02-11"},{"id":"48bd9dcf-d292-48b2-a409-af70759d67b7","acronym":"Brightline-4","url":"https://clinicaltrials.gov/study/NCT06058793","created_at":"2023-09-28T14:10:28.336Z","updated_at":"2025-02-25T15:20:51.763Z","phase":"Phase 3","brief_title":"Brightline-4: A Study to Test How Well Brigimadlin is Tolerated by People With a Type of Cancer Called Dedifferentiated Liposarcoma","source_id_and_acronym":"NCT06058793 - Brightline-4","lead_sponsor":"Boehringer Ingelheim","biomarkers":" MDM2","pipe":" | ","alterations":" MDM2 amplification","tags":["MDM2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MDM2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e brigimadlin (BI 907828)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 138","initiation":"Initiation: 12/13/2023","start_date":" 12/13/2023","primary_txt":" Primary completion: 07/07/2025","primary_completion_date":" 07/07/2025","study_txt":" Completion: 07/07/2025","study_completion_date":" 07/07/2025","last_update_posted":"2025-02-10"},{"id":"d1947b42-42fd-4782-93fd-228a17b831b3","acronym":"","url":"https://clinicaltrials.gov/study/NCT05372367","created_at":"2022-05-12T14:59:38.525Z","updated_at":"2025-02-25T16:39:01.449Z","phase":"Phase 1","brief_title":"A Study in People With Advanced Cancer to Test Whether the Amount of BI 907828 in the Blood is Influenced by Taking an OATP Inhibitor or a CYP3 Inhibitor","source_id_and_acronym":"NCT05372367","lead_sponsor":"Boehringer Ingelheim","biomarkers":" TP53","pipe":" | ","alterations":" TP53 wild-type","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e brigimadlin (BI 907828) • itraconazole • rifampicin"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 34","initiation":"Initiation: 08/11/2022","start_date":" 08/11/2022","primary_txt":" Primary completion: 07/17/2024","primary_completion_date":" 07/17/2024","study_txt":" Completion: 06/13/2025","study_completion_date":" 06/13/2025","last_update_posted":"2025-02-07"},{"id":"69e83241-ea93-4a7c-a2c5-2fc40b9cacd4","acronym":"","url":"https://clinicaltrials.gov/study/NCT03964233","created_at":"2021-01-18T19:30:14.916Z","updated_at":"2024-07-02T16:34:27.457Z","phase":"Phase 1","brief_title":"A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) and BI 754111 or BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab)","source_id_and_acronym":"NCT03964233","lead_sponsor":"Boehringer Ingelheim","biomarkers":" TP53 • MDM2","pipe":" | ","alterations":" TP53 mutation • TP53 wild-type • TP53 amplification","tags":["TP53 • MDM2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • TP53 wild-type • TP53 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e brigimadlin (BI 907828) • ezabenlimab (BI 754091) • miptenalimab (BI 754111)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 119","initiation":"Initiation: 06/11/2019","start_date":" 06/11/2019","primary_txt":" Primary completion: 09/03/2024","primary_completion_date":" 09/03/2024","study_txt":" Completion: 05/30/2026","study_completion_date":" 05/30/2026","last_update_posted":"2024-06-11"},{"id":"8945fb8d-c675-4151-861b-f34bbc81d66c","acronym":"Brightline-1","url":"https://clinicaltrials.gov/study/NCT05218499","created_at":"2022-02-05T18:28:26.477Z","updated_at":"2024-07-02T16:35:02.156Z","phase":"Phase 2/3","brief_title":"Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma","source_id_and_acronym":"NCT05218499 - Brightline-1","lead_sponsor":"Boehringer Ingelheim","biomarkers":" MDM2","pipe":" | ","alterations":" MDM2 amplification","tags":["MDM2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MDM2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • brigimadlin (BI 907828)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 400","initiation":"Initiation: 03/25/2022","start_date":" 03/25/2022","primary_txt":" Primary completion: 04/16/2024","primary_completion_date":" 04/16/2024","study_txt":" Completion: 05/27/2026","study_completion_date":" 05/27/2026","last_update_posted":"2024-05-22"},{"id":"96a72c38-5254-4a8a-8d13-048c6238a111","acronym":"EMPIRE","url":"https://clinicaltrials.gov/study/NCT06084689","created_at":"2023-10-16T15:12:55.518Z","updated_at":"2024-07-02T16:35:32.276Z","phase":"Phase 2","brief_title":"Targeting MDMD and PD1 in Tumors With Tertiary Lymphoid Structures","source_id_and_acronym":"NCT06084689 - EMPIRE","lead_sponsor":"Institut Bergonié","biomarkers":" PD-L1 • TP53","pipe":" | ","alterations":" TP53 wild-type","tags":["PD-L1 • TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e brigimadlin (BI 907828) • ezabenlimab (BI 754091)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 01/01/2024","start_date":" 01/01/2024","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2023-10-20"}]